Has Beverly Biller, MD received payments from drug or device companies?

Yes. Drug and device makers reported $346,078 in general payments to Beverly Biller, MD across 173 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Beverly Biller, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Beverly Biller, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Beverly Biller, MD

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1295726479

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 16.4%. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$346,078in general payments, 2019–2025

Across 173 payments — averaging $2000.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$57K
Novo Nordisk Health Care AG$55K
Recordati_rare_diseases_inc.$51K
H. Lundbeck A S$44K
Merck Kgaa$22K
AstraZeneca$21K
plus $97K from 11 others

$185,297in research payments, 2019–2025

Across 39 payments — averaging $4751.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ascendis Pharma Endocrinology Inc$159K
Novartis$17K
Pfizer$7K
Strongbridge US Inc.$2K
OPKO Pharmaceuticals, LLC$228

What the payments were for

Consulting fees$151,02844%
Speaking & faculty fees$94,51027%
Travel & lodging$97,52428%
Food & beverage$3,0151%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	29	$56,606
Novo Nordisk Health Care AG	35	$55,363
Recordati_rare_diseases_inc.	16	$50,680
H. Lundbeck A S	9	$43,905
Merck Kgaa	2	$21,545
AstraZeneca	12	$21,233
Ascendis Pharma Endocrinology Inc	13	$20,966
Xeris Pharmaceuticals, Inc.	11	$18,052
Neurocrine Biosciences, Inc.	11	$14,035
Novo Nordisk AS	7	$10,956
Amryt Pharma Holdings Ltd	6	$10,073
Strongbridge US Inc.	7	$7,425
Chiesi USA, Inc.	9	$5,632
Whitehall International Inc	1	$3,000
HRA Pharma RARE Diseases	2	$2,500
Novartis	2	$2,385
Ipsen Biopharmaceuticals, Inc	1	$1,720

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Norditropin$78,735
ISTURISA$22,544
SKYTROFA$20,721
OSILODROSTAT$18,762
RECORLEV$17,855
MYCAPSSA$15,538
SOMAVERT$3,000
METOPIRONE$2,500
Sogroya$2,210
SOMATULINE DEPOT$1,720

How this compares

$346,078 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$5,061

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
GenotropinSomatropin	21	$26,395
Testosterone	19	$1,631
Prednisone	24	$565
Levothyroxine Sodium	23	$326

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Boston

Jason GagliaBoston$2.4M
Vanita ArodaBoston$482K
Michael RosenblattBoston$447K
Steven RussellBoston$445K
Christos MantzorosBoston$243K
Augusto Caballero-RoblesBoston$150K
Osama HamdyBoston$117K
Barbara KahnBoston$105K
Naomi FisherBoston$79K
Andrea CovielloBoston$67K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →